The case for an HIV cure and how to get there

Dybul, Mark; Attoye, Timothy; Baptiste, Solange; Cherutich, Peter; Dabis, François; Deeks, Steven G.; Dieffenbach, Carl W.; Doehle, Brian P.; Goodenow, Maureen M.; Jiang, Adam; Kemps, Dominic; Lewin, Sharon R; Mathae, Lauren; McCune, Joseph M.; Ndung’u, Thumbi; Nsubuga, Moses Supercharger; Peay, Holly; Pottage, John C.; Warren, Mitchell; Sikazwe, Izukanji

doi:10.1016/s2352-3018(20)30232-0

Cited by 55 publications

(44 citation statements)

References 46 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another key characteristic of these target product profiles is that many of the products they describe are relatively early in the development pipeline, likely a decade or more away from the clinic. Based on considerations described the in HIV Cure Africa Acceleration Partnership report by Dybul and colleagues 28 we think that the timely establishment of an HIV cure target product profile will help catalyse early product development, accelerate the development process, and ensure rapid uptake, especially in low-income to middle-income countries, once a product has been developed. Even at this relatively early stage, these target product profiles can be adopted as the basis for all stakeholders, including industry leaders guiding product development within their organisations, research funders supporting basic HIV cure research, or community advocates hoping to share a realistic vision of an HIV cure.…”

Section: Discussionmentioning

confidence: 99%

“…Going forward, the continuous stewardship of these documents will be a core remit of the HIV Cure Africa Acceleration Partnership. 28 The first successful HIV cure that begins to address the needs of people living with HIV and that frees them from daily ART might be a decade or more away. Although, to provide important guidance to developers and to manage the expectations of the global community, now is the time to begin to define the characteristics of such an intervention.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Multi-stakeholder consensus on a target product profile for an HIV cure

et al. 2021

Self Cite

View full text Add to dashboard Cite

Developing a cure for HIV is a global priority. Target product profiles are a tool commonly used throughout the drug development process to align interested parties around a clear set of goals or requirements for a potential product. Three distinct therapeutic modalities (combination therapies, ex-vivo gene therapy, and in-vivo gene therapy) for a target product profile for an HIV cure were identified. Using a process of expert face-to-face consultation and an online Delphi consultation, we found a high degree of agreement regarding the criteria for the optimum target product profile. Although the minimum attributes for a cure were debated, the broad consensus was that an acceptable cure need not be as safe and effective as optimally delivered antiretroviral therapy. An intervention that successfully cured a reasonable fraction of adults would be sufficient to advance to the clinic. These target product profiles will require further discussion and ongoing revisions as the field matures.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Multi-stakeholder consensus on a target product profile for an HIV cure

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Additionally, there are barriers to universal ART uptake that include toxicities, stigma, and the need for lifelong adherence (8)(9)(10). Therefore, alternative ART-free strategies that confer durable viral suppression, prevent disease progression, and avoid drug resistance are highly desirable (11,12). Proposed minimal target profiles for these strategies include the ability to maintain plasma HIV-1 RNA below the level at which transmission occurs, for at least 2 years, and be generally safe and tolerated (13).…”

Section: Introductionmentioning

confidence: 99%

Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?

2021

View full text Add to dashboard Cite

Many broadly neutralizing antibodies (bnAbs) targeting the HIV-1 envelope glycoprotein are being assessed in clinical trials as strategies for HIV-1 prevention, treatment, and antiretroviral-free remission. BnAbs can neutralize HIV-1 and target infected cells for elimination. Concerns about HIV-1 resistance to single bnAbs have led to studies of bnAb combinations with non-overlapping resistance profiles. This review focuses on the potential for bnAbs to induce HIV-1 remission, either alone or in combination with latency reversing agents, therapeutic vaccines or other novel therapeutics. Key topics include preliminary activity of bnAbs in preclinical models and in human studies of HIV-1 remission, clinical trial designs, and antibody design strategies to optimize pharmacokinetics, coverage of rebound-competent virus, and enhancement of cellular immune functions.

show abstract

“…Recent overviews from the field indicate that HIV cure research should be conducted in more diverse settings and benefits from timely defining target product profiles. 1 , 2 , 3 These should contain key parameters such as the efficacy, toxicity and necessary infrastructure of potential future cure interventions for which research and early stakeholder engagement are essential. We fully agree with this perspective and would like to contribute with a joint action to materialize this strategy.…”

mentioning

confidence: 99%

“…Next to existing national and international HIV cure study networks (e.g. EPIICAL, https://www.epiical.org/ ; ACTG, https://actgnetwork.org/studies/ ; IAS-Cure, https://iasociety.org/hivcure ; CHERUB, https://www.cherub.uk.net/ ;) and the more recently launched Dutch NL4Cure and African HIV Cure Africa Acceleration Partnership (HCAAP) initiatives), 3 , 4 we believe that there is a need to establish a complimentary European HIV Cure Research Consortium which has been named EU2Cure. This network will help to intensify collaborations primarily amongst Europe’s HIV cure research groups.…”

mentioning

confidence: 99%

Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure Consortium

Rokx

Prins

Vandekerckhove

et al. 2021

Journal of Virus Eradication

View full text Add to dashboard Cite

We felt the urgency to launch the EU2Cure Consortium to support research and find a cure for the human immunodeficiency virus (HIV) infection through intensified collaboration within Europe. This consortium is open to stakeholders on cure in Europe from academia and the community to connect. The aim of this consortium is to intensify the research collaboration amongst European HIV cure groups and the community and facilitate interactions with other academic and community cure consortia, private parties, and policy makers. Our main aim is to create a European research agenda, data sharing, and development of best practice for clinical and translational science to achieve breakthroughs with clinically feasible HIV cure strategies. This consortium should also enable setting up collaborative studies accessible to a broader group of people living with HIV. Besides reservoir studies, we have identified three overlapping scientific interests in the consortium that provide a starting point for further research within a European network: developing “shock and kill” cure strategies, defining HIV cure biomarkers, and connecting cure cohorts. This strategy should aid stakeholders to sustain progress in HIV cure research regardless of coincidental global health or political crises.

show abstract

The case for an HIV cure and how to get there

Cited by 55 publications

References 46 publications

Multi-stakeholder consensus on a target product profile for an HIV cure

Multi-stakeholder consensus on a target product profile for an HIV cure

Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?

Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure Consortium

Contact Info

Product

Resources

About